



Company Overview

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as graft-vs-host disease (GvHD) and NASH.

CytoDyn to Hold Webcast on May 5 to Provide Update on Multiple Initiatives

May 3 2021, 9:05 AM EDT

Data from 10 Patients with Stage Four Cancer Treated with Leronlimab for Nearly One Year Will Serve as Basis for Pre-Breakthrough Therapy Designation Meeting with FDA

May 3 2021, 9:02 AM EDT

CytoDyn HIV Indication Update: Leronlimab HIV Extension Arm Nearing 7 Years with Continued Excellent Safety Results

May 3 2021, 9:00 AM EDT

Stock Overview

Symbol	CYDY
Exchange	OTCQB
Market Cap	1.91b
Last Price	\$3.12
52-Week Range	\$1.63 - \$10.02

05/03/2021 03:59 PM EDT

Management Team

Nader Z. Pourhassan, Ph.D.

Director, President and CEO

Scott A. Kelly, M.D.

Chief Medical Officer, Head of Business Development and Chairman of the Board

Nitya G. Ray, Ph.D.

Chief Technology Officer - Head of Process Sciences, Manufacturing & Supply Chain

Michael D. Mulholland

Chief Financial Officer

Christopher Recknor, M.D.

Chief Operating Officer and Head of Clinical Development

CytoDyn Inc.

1111 Main Street
Suite 660
Vancouver, WA 98660

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.